Donald Bergstrom Sells 8,530 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 8,530 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.97, for a total transaction of $161,814.10. Following the completion of the sale, the insider owned 399,130 shares of the company’s stock, valued at $7,571,496.10. This trade represents a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Relay Therapeutics Trading Up 1.2%

Shares of Relay Therapeutics stock opened at $18.89 on Friday. Relay Therapeutics, Inc. has a 12-month low of $3.88 and a 12-month high of $21.27. The firm has a market capitalization of $4.14 billion, a price-to-earnings ratio of -12.03 and a beta of 1.69. The firm’s 50 day simple moving average is $19.37 and its two-hundred day simple moving average is $15.41.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. On average, sell-side analysts predict that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on RLAY shares. Barclays lifted their price target on Relay Therapeutics from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Guggenheim reissued a “buy” rating on shares of Relay Therapeutics in a report on Friday, August 7th. HC Wainwright raised their price objective on Relay Therapeutics from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Citizens Jmp lifted their target price on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a report on Monday, August 10th. Finally, UBS Group set a $26.00 target price on Relay Therapeutics in a research report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Relay Therapeutics during the 2nd quarter worth about $286,042,000. Commodore Capital LP acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at about $46,191,000. Casdin Capital LLC lifted its holdings in shares of Relay Therapeutics by 14.7% in the 4th quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock valued at $110,010,000 after buying an additional 1,662,193 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Relay Therapeutics by 412.3% in the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after buying an additional 7,847,896 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after buying an additional 295,701 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.